
|Videos|October 2, 2020
Bayer discusses relevant clinical study results
Author(s)Modern Retina Staff Reports
Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.
Advertisement
Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Timely interventions can protect vision in patients with GA
2
FLORetina 2025: Long-term follow-up in pediatric gene therapy
3
Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal Vascular Diseases
4
Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
5








































